Term
|
Definition
| NSAID (acute gout attack) |
|
|
Term
|
Definition
| NSAID (acute gout attack, migraine) |
|
|
Term
|
Definition
| injectable NSAID (acute gout attack) |
|
|
Term
|
Definition
| binds tubulin inhibiting gout specific inflammation (acute gout attack) |
|
|
Term
|
Definition
| xanthine oxidase inhibitor--decreasing formation of uric acid (prophylaxis for gout in patients who are producing excess uric acid or have existing kidney stones) |
|
|
Term
|
Definition
| xanthine oxidase inhibitor--decreasing formation of uric acid (prophylaxis for gout in patients who are producing excess uric acid or have existing kidney stones) |
|
|
Term
|
Definition
| inhibits secretion and reabsorption of uric acid (prophylaxis of gout in patients who do not normally excrete large amounts of uric acid in the urine) |
|
|
Term
|
Definition
| recombinant urate-oxidase/uricase enzyme--converts uric acid to allantoin (prophylaxis of gout in pediatric patients receiving anticancer therapy or severe refractory gout) |
|
|
Term
|
Definition
| recombinant urate-oxidase/uricase enzyme--converts uric acid to allantoin (prophylaxis of severe refractory gout) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| ergotamine tartrate (ergomar, ercaf, cafergot) |
|
Definition
| 5-HT1B receptor agonist--vasoconstriction and reduce neurogenic inflammation (2nd line therapy for acute treatment of migraine) |
|
|
Term
| dihydroergotamine (D.H.E. 45) |
|
Definition
| 5-HT1B receptor agonist--vasoconstriction and reduce neurogenic inflammation (2nd line therapy for acute treatment of migraine) |
|
|
Term
|
Definition
| 1st gen triptan serotonin derivative--vasoconstriction and reduce neurogenic inflammation (1st line treatment for migraine) |
|
|
Term
| zolmitriptan (zomig, zomig ZMT) |
|
Definition
| 2nd gen triptan serotonin derivative--vasoconstriction and reduce neurogenic inflammation, centrally inhibits pain transmission in trigeminal nucleus (1st line treatment for migraine) |
|
|
Term
|
Definition
| dopamine antagonist (acute migraine, antiemetic) |
|
|
Term
| prochlorperazine (compazine) |
|
Definition
| dopamine antagonist (acute migraine, antiemetic) |
|
|
Term
| chlorpromazine (thorazine) |
|
Definition
| dopamine antagonist (acute migraine, antiemetic) |
|
|
Term
|
Definition
| B blocker (prophylaxis of migraine, anxiolytic--stage fright) |
|
|
Term
|
Definition
| B blocker (prophylaxis of migraine) |
|
|
Term
|
Definition
| B blocker (prophylaxis of migraine) |
|
|
Term
|
Definition
| B blocker (prophylaxis of migraine) |
|
|
Term
|
Definition
| B blocker (prophylaxis of migraine) |
|
|
Term
|
Definition
| down regulation of central 5-HT2 and adrenergic receptors (prophylaxis of migraine) |
|
|
Term
| valproic acid (depakote, depakene) |
|
Definition
| increases GABA synthesis, modulates glutamate and inhibits sodium channel reactivation and T-type Ca+ channels (prophylaxis of migraine, absence, myoclonic, partial and tonic/clonic seizures) |
|
|
Term
| botulinum toxin type A (botox) |
|
Definition
| migraine, medication rebound migraine |
|
|
Term
|
Definition
| facilitates GABA neurotransmission, modulates glutamate and inhibits sodium and calcium channel activity (prophylaxis of migraine, partial seizures, neuropathic pain) |
|
|
Term
|
Definition
| long acting barbituate--GABA receptor agonist (generalized tonic-clonic and partial seizures, status epilepticus) |
|
|
Term
| Phenytoin (dilantin, diphenylan) |
|
Definition
| prolong recovery rate of voltage-gated Na+ channels (generalized tonic-clonic and partial seizures, status epilepticus) |
|
|
Term
| carbamazepine 1974 (tegretol, carbatrol) |
|
Definition
| prolong recovery rate of voltage-gated Na+ channels (generalized tonic-clonic and partial seizures, manic-depressive patients) |
|
|
Term
| oxcarbazepine 2000 (trileptal) |
|
Definition
| prolong recovery rate of voltage-gated Na+ channels (partial seizures) |
|
|
Term
| ethosuximide 1960 (zarontin) |
|
Definition
| inhibits T-type Ca+ channels (absence seizures) |
|
|
Term
| lamotrigine-1994 (lamictal) |
|
Definition
| prolong recovery rate of voltage-gated Na+ channels (partial and generalized tonic/clonic seizures, "broad spectrum" AED) |
|
|
Term
| topiramate 1996 (topomax) |
|
Definition
| inhibits Na channels, AMPA-kainate receptors, and enhances GABA receptors (partial and tonic/clonic seizures, "broad spectrum" AED, prophylaxis of migraine) |
|
|
Term
| levetiracetam-1999 (keppra) |
|
Definition
| partial and tonic/clonic seizures in adults and myoclonic seizures in children, status epilepticus |
|
|
Term
| L-DOPA (larodopa, sinemet) |
|
Definition
| dopamine precursor (parkinsons) |
|
|
Term
|
Definition
| DOPA decarboxylase inhibitor in periphery (combo with L-DOPA for parkinsons) |
|
|
Term
|
Definition
| carbidopa+L-DOPA (parkinsons) |
|
|
Term
|
Definition
| ergot derivative--nonspecific DA receptor agonist (parkinsons) |
|
|
Term
|
Definition
| non-ergot dopamine receptor agonist (parkinsons, restless leg syndrome) |
|
|
Term
|
Definition
| non-ergot dopamine receptor agonist (parkinsons, restless leg syndrome) |
|
|
Term
|
Definition
| stimulates dopamine release (parkinsons, antiviral) |
|
|
Term
| selegiline/deprenyl (eldepryl, zelapar) |
|
Definition
| MAO-B inhibitor--prevents DA breakdown in CNS (late parkinsons) |
|
|
Term
|
Definition
| MAO-B inhibitor--prevents DA breakdown in CNS (early and late parkinsons) |
|
|
Term
|
Definition
| COMT inhibitor--inhibits metabolism of DA (parkinsons) |
|
|
Term
|
Definition
| L-DOPA+carbidopa+entacapone |
|
|
Term
|
Definition
| anticholinergic (iatrogenic parkinsonism--drug induced) |
|
|
Term
|
Definition
| anticholinergic (iatrogenic parkinsonism--drug induced) |
|
|
Term
| diphenhydramine (benadryl) |
|
Definition
| antihistamine w/ anticholinergic activity (iatrogenic parkinsonism) |
|
|
Term
|
Definition
|
|
Term
|
Definition
| short duration benzodiazepine (anesthesia) |
|
|
Term
|
Definition
| short duration benzodiazepine (hypnotic-insomnia) |
|
|
Term
|
Definition
| intermediate duration benzodiazepine (hypnotic-insomnia) |
|
|
Term
|
Definition
| intermediate duration benzodiazepine (hypnotic, anxiolytic, anesthesia, withdrawal suppressant, status epilepticus) |
|
|
Term
|
Definition
| intermediate duration benzodiazepine (anxiolytic) |
|
|
Term
| chlordiazepoxide (librium) |
|
Definition
| long duration benzodiazepine (anxiolytic, anticonvulsant, withdrawal suppressant) |
|
|
Term
|
Definition
| long duration benzodiazepine (anxiolytic, anticonvulsant, anesthesia, withdrawal suppressant, muscle relaxant) |
|
|
Term
|
Definition
| intermediate duration barbituate (hypnotic-insomnia) |
|
|
Term
|
Definition
| intermediate duration barbituate (hypnotic-insomnia) |
|
|
Term
|
Definition
| ultra short duration barbituate (anesthesia) |
|
|
Term
|
Definition
| partial 5-HT1A receptor agonist (anxiolytic, hypnotic-insomnia, muscle relaxant--especially in patients with history of drug abuse) |
|
|
Term
|
Definition
| enhance GABA effects (hypnotic-insomnia) |
|
|
Term
|
Definition
| enhance GABA effects (hypnotic-insomnia) |
|
|
Term
|
Definition
| enhance GABA effects (hypnotic-insomnia) |
|
|
Term
| gammahydroxybutyrate (GHB) |
|
Definition
| GABA analog (date rape drug, liquid ecstasy, easy lay, georgia home boy) |
|
|
Term
|
Definition
| pineal gland hormone (sleep aid) |
|
|
Term
|
Definition
| melatonin receptor agonist (sleep aid) |
|
|
Term
|
Definition
| benzodiazepine antagonist (post anesthesia, benzo poisoning) |
|
|
Term
|
Definition
| GABA analog at GABA-B receptors in spinal cord (spasticity from MS and spinal cord injuries) |
|
|
Term
| cyclobenzaprene (flexeril) |
|
Definition
| inhibits gamma and alpha motor systems (muscles spasms of local origin--strains) |
|
|
Term
|
Definition
| alpha-2 adrenergic agonist (muscle relaxant) |
|
|
Term
|
Definition
|
|
Term
|
Definition
| aldehyde dehydrogenase inhibitor (alcoholism) |
|
|
Term
|
Definition
| long acting opioid antagonist (reduce ETOH craving) |
|
|
Term
|
Definition
| reduce ETOH cravings--alcoholics with liver problems |
|
|
Term
|
Definition
| atypical antipsychotic (managing psychiatric side effects of L-DOPA) |
|
|
